Feature | Pharmaceuticals | October 25, 2023 | By Christine Book

Hypertrophic Cardiomyopathy Video Series with Christine E. Seidman, MD, FACC, FAHA

3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor Christine Book sat down with the cardiovascular research leader to learn more about the critical work and research she is conducting in this field.

In the first of this 3-part “One on One” series, Dr. Christine Seidman — recognized as one of the world’s most respected physician scientists — delves into the research and treatments of the heart muscle disorder, hypertrophic cardiomyopathy. Watch Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

In part 2 of DAIC’s 3-part “One on One” series with Dr. Christine Seidman, a discussion on the discovery of gene-based diagnostics at Harvard’s Seidman Lab which allowed for targeted disease treatment of hypertrophic cardiomyopathy. Watch Part 2: Hypertrophic Cardiomyopathy in Focushere.

In the third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at Harvard’s Seidman Lab, and how she views the value of learning from and mentoring a new generation of researchers. Watch Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

Related Hypertrophic Cardiomyopathy content:

Part 1: Hypertrophic Cardiomyopathy: One on One with a Cardiovascular Research Leader

Part 2: Hypertrophic Cardiomyopathy in Focus

Part 3: Award-winning Researcher Shares Update on Hypertrophic Cardiomyopathy Work and Value of Mentoring

Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina

Results from Two Phase 3 Studies Evaluating Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy Released

First International Guidelines on Heart Muscle Diseases Published


Related Content

News | Pharmaceuticals

Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 ...

Home January 28, 2026
Home
News | Pharmaceuticals

Nov. 19, 2025 — Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were ...

Home November 19, 2025
Home
News | Pharmaceuticals

Sept. 25, 2025 — Kardigan has introduced the three late-stage clinical programs leading its robust pipeline, each ...

Home September 25, 2025
Home
News | Pharmaceuticals

Sept. 23, 2025 — CeleCor Therapeutics’ multinational Phase 3 clinical trial of its investigational heart-attack drug ...

Home September 23, 2025
Home
News | Pharmaceuticals

Sept. 2, 2025 —Corsera Health, Inc. has announced its launch with a mission to extend healthspan through cardiovascular ...

Home September 05, 2025
Home
News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
Subscribe Now